Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
Autonomix Medical (NASDAQ: AMIX), a company specializing in medical devices for nervous system diseases, will participate in the Virtual Investor Closing Bell Series on May 16, 2024, at 4:00 PM ET. CEO Lori Bisson will present a corporate overview and business outlook. The event will be live-streamed on the company's website, with an opportunity for live questions from investors. A replay will be available for 90 days post-event.
- Participation in high-visibility event: Virtual Investor Closing Bell Series.
- Opportunity for real-time investor engagement and Q&A.
- Webcast replay available for 90 days, enhancing accessibility.
- No new product launches or financial updates were announced.
- Details on business strategies and financial performance were not provided.
Live webcast on Thursday, May 16th at 4:00 PM ET
THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Thursday, May 16, 2024 at 4:00 PM ET.
As part of the event, Lori Bisson, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com
FAQ
When is Autonomix Medical participating in the Virtual Investor Closing Bell Series?
Who will present at the Virtual Investor Closing Bell Series for Autonomix Medical?
How can I watch the webcast of the Virtual Investor Closing Bell Series?
Will there be a replay of the Autonomix Medical webcast?